Cancer Radiotheranostics: Principles and Clinical Applications in Nuclear Medicine
First Edition 2026 | Sean L. Kitson, PhD
Cancer Radiotheranostics: Principles and Clinical Applications in Nuclear Medicine provides an authoritative and accessible guide to one of the fastest-developing areas of precision oncology. Bringing together molecular imaging, targeted radionuclide therapy, radiopharmaceutical science and clinical practice, the book explains the principles that underpin modern radiotheranostics and examines how they are being translated into cancer care.
Written for clinicians, scientists, radiopharmacists, radiochemists, medical physicists, researchers and trainees, the book progresses from the foundations of nuclear medicine through established treatments to investigational radiopharmaceuticals, emerging molecular targets and future directions.
Available in hardback from Amazon
Buy Cancer Radiotheranostics on Amazon
About the Book
Radiotheranostics links molecular imaging with targeted radionuclide therapy through shared biological targets. Diagnostic radiopharmaceuticals can identify whether a tumour expresses a clinically relevant target and show the distribution of disease throughout the body. Related therapeutic radiopharmaceuticals can then be used to deliver radiation to those same biological sites.
This approach connects diagnosis, patient selection, treatment planning, therapy, dosimetry, monitoring and follow-up within a precision oncology framework.
Cancer Radiotheranostics examines this rapidly developing field across 63 chapters organised into four thematic parts, taking the reader from fundamental principles to current clinical applications and next-generation technologies.
What the Book Covers
The book begins with the scientific foundations of radiotheranostics, including radiopharmaceutical design, radioactivity, molecular targeting, therapeutic emissions, dosimetry and medical physics. Dedicated chapters examine the principal imaging technologies used in the field, including PET, SPECT, MRI and CT.
Clinical sections examine established and developing radiopharmaceutical therapies, including applications of lutetium-177 in prostate cancer and neuroendocrine tumours. The book also considers yttrium-90, lead-212, gallium-68, zirconium-89 and copper radionuclides, together with the growing interest in targeted alpha therapy.
A substantial part of the book is devoted to emerging radiopharmaceutical development. Molecular targets discussed include:
- PSMA – prostate-specific membrane antigen
- FAP – fibroblast activation protein
- GRPR – gastrin-releasing peptide receptor
- CXCR4 – C-X-C motif chemokine receptor 4
- CAIX – carbonic anhydrase IX
- CCK2R – cholecystokinin-2 receptor
- NTSR1 – neurotensin receptor 1
The later chapters address the wider requirements for successful radiotheranostics, including radionuclide production and supply, radiopharmacy operations, GMP manufacture, patient experience, artificial intelligence, reimbursement, health economics and service implementation.
Landmark Clinical Evidence
Modern radiotheranostics has been shaped by major clinical trials demonstrating how molecular imaging and targeted radionuclide therapy can contribute to cancer treatment.
The book includes a dedicated chapter examining landmark clinical trials and places important evidence from studies such as NETTER-1 and VISION within the development of modern radiotheranostics.
It also examines investigational agents and treatment strategies that may influence how radiotheranostics develops in future clinical practice.
Key Features
- 63 chapters covering the foundations, clinical applications and future of radiotheranostics
- Four clearly organised thematic parts
- Detailed coverage of molecular imaging and targeted radionuclide therapy
- Dedicated discussion of lutetium-177 and other important radionuclides
- Established and investigational radiopharmaceuticals
- Emerging targets including PSMA, FAP, GRPR, CXCR4, CAIX and CCK2R
- PET, SPECT, MRI and CT imaging
- Personalised dosimetry and clinical workflow
- Radiopharmacy operations and GMP manufacture
- Radionuclide production and global supply
- Artificial intelligence and digital technologies
- Patient experience and multidisciplinary care
- Reimbursement and health economics
- Landmark clinical trials
- Next-generation radiotheranostics and targeted alpha therapy
- Chapter summaries, keywords and tables
- Glossary of key terms and reference appendices
- Extensive scientific references, including literature published in 2025 and 2026
Who Is This Book For?
Cancer Radiotheranostics has been written for readers working in, studying or seeking to understand nuclear medicine and precision oncology, including:
Nuclear medicine physicians • Oncologists • Radiologists • Radiopharmacists • Radiochemists • Medical physicists • Scientists • Researchers • Technologists • Postgraduate students • Clinical trainees
The book is designed both as an introduction to the principles of radiotheranostics and as a reference for readers interested in current treatments, investigational agents and the scientific and clinical direction of the field.
Four-Part Structure
Part 1 – Foundations of Radiotheranostics
Introduces radiopharmaceuticals, radioactivity, theranostics, targeted radionuclide therapy, therapeutic emissions, dosimetry, medical physics, molecular imaging and targeting agents.
Part 2 – Clinical Applications and Emerging Directions
Examines important clinical applications of lutetium-177 radiopharmaceuticals, including prostate cancer and neuroendocrine tumours, alongside personalised dosimetry and clinical workflow.
Part 3 – Emerging Targets and Investigational Agent Development
Explores investigational radiopharmaceuticals across PSMA, FAP, GRPR, CXCR4, CAIX and other molecular targets and tumour settings.
Part 4 – Platform Techniques, Supply, and Where the Field Is Going
Covers radionuclide production, radiopharmacy, GMP manufacture, lutetium-177, yttrium-90, lead, gallium, zirconium and copper radiopharmaceuticals, patient experience, artificial intelligence, health economics, landmark clinical trials and next-generation radiotheranostics.
About the Author
Sean L. Kitson, PhD is a radiochemist, scientific author and editor with experience in radiochemistry, radiopharmaceutical science and scientific publishing. He has authored more than 50 scientific publications and has contributed to specialist scientific communication through journal publishing and Open MedScience.
Book Details
Title: Cancer Radiotheranostics: Principles and Clinical Applications in Nuclear Medicine
Author: Sean L. Kitson, PhD
Edition: First Edition
Publication year: 2026
Format: Hardback
ISBN: 978-1-0369-9760-1
Publisher: Open MedScience Limited, United Kingdom
Order Cancer Radiotheranostics
Discover the science, clinical applications and emerging technologies shaping the future of cancer radiotheranostics.
Buy Cancer Radiotheranostics on Amazon
Medical Disclaimer: This book and promotional page are provided for educational and informational purposes only. They are not intended to provide medical advice, diagnosis or treatment, nor should they replace independent clinical judgement, specialist training, current prescribing information, institutional protocols or applicable regulations. Clinical decisions should always be made by appropriately qualified healthcare professionals using current evidence and guidance.
home »